Discharge heart rate and future events among Japanese patients with acute heart failure receiving beta-blocker therapy


Background: Randomized trials have demonstrated the efficacy of beta-blockers (BBs) in heart failure (HF) patients. We sought to assess the impact of BBs on long-term outcome; in particular, we assessed the association between outcome and BB dose and discharge heart rate. Methods and Results: Prescriptions for dispensed medication and outcomes were identified from a prospective, single-institution HF registry. Long-term prognosis was compared between users and non-users of BBs. BB users were further divided into 2 groups based on dose (full and non-full dose) and discharge heart rate (<70 bpm and ≥70 bpm). The primary endpoint was defined as either death or hospitalization due to HF. Of 199 patients, 158 (79.4%) were receiving BBs at discharge. Their mean age was 66.8 ± 15.84 years. Compared with non-users of BBs, BB users were younger (65.0 ± 15.5 vs 73.8 ± 13.3 years, P = 0.001) and had a lower ejection fraction (36.0% ± 14.0% vs 48.3% ± 11.7%, p < 0.001). The use of BBs had no effect on long-term outcome (HR = 2.564, P = 0.246), whereas the event-free rate was significantly decreased with increasing heart rate (stratified by 70 bpm; log-rank P = 0.05). A discharge heart rate of >70 bpm was significantly associated with impaired long-term outcome (HR = 1.872, P = 0.04). Conclusions: Optimizing heart rate, rather than maximizing BB dose, appears to be an appropriate treatment strategy for the beta-sensitive Japanese population.

Share and Cite:

Oshima, K. , Kohsaka, S. , Koide, K. , Nagatomo, Y. , Nagai, T. , Endo, Y. , Yoshikawa, T. and Fukuda, K. (2013) Discharge heart rate and future events among Japanese patients with acute heart failure receiving beta-blocker therapy. World Journal of Cardiovascular Diseases, 3, 159-167. doi: 10.4236/wjcd.2013.31A023.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Hunt, S.A., Abraham, W.T., Chin, M.H., Feldman, A.M., Francis, G.S., Ganiats, T.G., Jessup, M., Konstam, M.A., Mancini, D.M., Michl, K., et al. (2009) 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation, 119, e391-e479. doi:10.1161/CIRCULATIONAHA.109.192065
[2] (1999) The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomised trial. Lancet, 353, 9-13. doi:10.1016/S0140-6736(98)11181-9
[3] Leizorovicz, A., Lechat, P., Cucherat, M. and Bugnard, F. (2002) Bisoprolol for the treatment of chronic heart failure: A meta-analysis on individual data of two placebocontrolled studies—CIBIS and CIBIS II. Cardiac insufficiency bisoprolol study. American Heart Journal, 143, 301-307. doi:10.1067/mhj.2002.120768
[4] Lechat, P., Escolano, S., Golmard, J.L., Lardoux, H., Witchitz, S., Henneman, J.A., Maisch, B., Hetzel, M., Jaillon, P., Boissel, J.P., et al. (1997) Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the cardiac insufficiency bisoprolol study (CIBIS). Circulation, 96, 2197-2205. doi:10.1161/01.CIR.96.7.2197
[5] CIBIS Investigators and Committees (1994) A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation, 90, 1765-1773.
[6] Hjalmarson, A., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vitovec, J., Aldershvile, J., et al. (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA, 283, 12951302. doi:10.1001/jama.283.10.1295
[7] Waagstein, F., Bristow, M.R., Swedberg, K., Camerini, F., Fowler, M.B., Silver, M.A., Gilbert, E.M., Johnson, M.R., Goss, F.G. and Hjalmarson, A. (1993) Beneficial effects of meto-prolol in idiopathic dilated cardiomyopathy. Lancet, 342, 1441-1446. doi:10.1016/0140-6736(93)92930-R
[8] Dargie, H.J. (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet, 357, 1385-1390. doi:10.1016/S0140-6736(00)04560-8
[9] Packer, M., Coats, A.J., Fowler, M.B., Katus, H.A., Krum, H., Mohacsi, P., Rouleau, J.L., Tendera, M., Castaigne, A., Roecker, E.B., et al. (2001) Effect of carvedilol on survival in severe chronic heart failure. The New England Journal of Medicine, 344, 1651-1658. doi:10.1056/NEJM200105313442201
[10] Colucci, W.S., Packer, M., Bristow, M.R., Gilbert, E.M., Cohn, J.N., Fowler, M.B., Krueger, S.K., Hershberger, R., Uretsky, B.F., Bowers, J.A., et al. (1996) Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation, 94, 2800-2806. doi:10.1161/01.CIR.94.11.2800
[11] Bristow, M.R., Gilbert, E.M., Abraham, W.T., Adams, K.F., Fowler, M.B., Hershberger, R.E., Kubo, S.H., Narahara, K.A., Ingersoll, H., Krueger, S., et al. (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation, 94, 2807-2816. doi:10.1161/01.CIR.94.11.2807
[12] Packer, M., Colucci, W.S., Sackner-Bernstein, J.D., Liang, C.S., Goldscher, D.A., Freeman, I., Kukin, M.L., Kinhal, V., Udelson, J.E., Klapholz, M., et al. (1996) Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRE-CISE Trial. Prospective randomized evaluation of carvedilol on symptoms and exercise. Circulation, 94, 2793-2799. doi:10.1161/01.CIR.94.11.2793
[13] Packer, M., Bristow, M.R., Cohn, J.N., Colucci, W.S., Fowler, M.B., Gilbert, E.M. and Shusterman, N.H. (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. The New England Journal of Medicine, 334, 1349-1355. doi:10.1056/NEJM199605233342101
[14] Fox, K., Ford, I., Steg, P.G., Tendera, M. and Ferrari, R. (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial. Lancet, 372, 807-816. doi:10.1016/S0140-6736(08)61170-8
[15] Fosbol, E.L., Seibaek, M., Brendorp, B., Moller, D.V., Thune, J.J., Gislason, G.H., Torp-Pedersen, C. and Kober, L. (2010) Long-term prognostic importance of resting heart rate in patients with left ventricular dysfunction in connection with either heart failure or myocardial infarction: The DIAMOND study. International Journal of Cardiology, 140, 279-286. doi:10.1016/j.ijcard.2008.11.084
[16] Zhou, H.H., Koshakji, R.P., Silberstein, D.J., Wilkinson, G.R. and Wood, A.J. (1989) Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. The New England Journal of Medicine, 320, 565-570. doi:10.1056/NEJM198903023200905
[17] Sanderson, J.E., Yu, C.M., Young, R.P., Shum, I.O., Wei, S., Arumanayagam, M. and Woo, K.S. (1999) Influence of gene polymorphisms of the reninangiotensin system on clinical outcome in heart failure among the Chinese. American Heart Journal, 137, 653-657. doi:10.1016/S0002-8703(99)70218-8
[18] Seow, S.C., Chai, P., Lee, Y.P., Chan, Y.H., Kwok, B.W., Yeo, T.C. and Chia, B.L. (2007) Heart failure mortality in Southeast Asian patients with left ventricular systolic dysfunction. Journal of Cardiac Failure, 13, 476-481. doi:10.1016/j.cardfail.2007.03.010
[19] Levey, A.S., Bosch, J.P., Lewis, J.B., Greene, T., Rogers, N. and Roth, D. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Annals of Internal Medicine, 130, 461-470.
[20] Jessup, M., Abraham, W.T., Casey, D.E., Feldman, A.M., Francis, G.S., Ganiats, T.G., Konstam, M.A., Mancini, D.M., Rahko, P.S., Silver, M.A., et al. (2009) 2009 focused update: ACCF/AHA Guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation, 119, 1977-2016. doi:10.1161/CIRCULATIONAHA.109.192064
[21] Dickstein, K., Cohen-Solal, A., Filippatos, G., McMurray, J.J., Ponikowski, P., Poole-Wilson, P.A., Stromberg, A., van Veldhuisen, D.J., Atar, D., Hoes, A.W., et al. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal, 29, 2388-2442. doi:10.1093/eurheartj/ehn309
[22] Cleland, J.G., Cohen-Solal, A., Aguilar, J.C., Dietz, R., Eastaugh, J., Follath, F., Freemantle, N., Gavazzi, A., van Gilst, W.H., Hobbs, F.D., et al. (2002) Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): An international survey. Lancet, 360, 1631-1639. doi:10.1016/S0140-6736(02)11601-1
[23] Chioncel, O., Vinereanu, D., Datcu, M., Ionescu, D.D., Capalneanu, R., Brukner, I., Dorobantu, M., Ambrosy, A., Macarie, C. and Gheorghiade, M. (2011) The Romanian acute heart failure syndromes (RO-AHFS) registry. American Heart Journal, 162, 142-153.
[24] Heidenreich, P.A., Hernandez, A.F., Yancy, C.W., Liang, L., Peterson, E.D. and Fonarow, G.C. (2012) Get with the guidelines program participation, process of care, and outcome for medicare patients hospitalized with heart failure. Circulation Cardiovascular Quality and Outcome, 5, 37-43.
[25] Fonarow, G.C., Abraham, W.T., Albert, N.M., Stough, W.G., Gheorghiade, M., Greenberg, B.H., O’Connor, C.M., Sun, J.L., Yancy, C.W. and Young, J.B. (2008) Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF program. Journal of the American College of Cardiology, 52, 190-199. doi:10.1016/j.jacc.2008.03.048
[26] Nochioka, K., Shiba, N., Kohno, H., Miura, M. and Shimokawa, H. (2010) Both high and low body mass indexes are prognostic risks in Japanese patients with chronic heart failure: Implications from the CHART study. Journal of Cardiac Failure, 16, 880-887. doi:10.1016/j.cardfail.2010.06.413
[27] Tsuchihashi-Makaya, M., Kinugawa, S., Yokoshiki, H., Hamaguchi, S., Yokota, T., Goto, D., Goto, K., Takeshita, A. and Tsutsui, H. (2010) Beta-blocker use at discharge in patients hospitalized for heart failure is associated with improved survival. Circulation Journal, 74, 1364-1371. doi:10.1253/circj.CJ-09-0993
[28] Bohm, M., Swedberg, K., Komajda, M., Borer, J.S., Ford, I., Dubost-Brama, A., Lerebours, G. and Tavazzi, L. (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): The association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet, 376, 886-894. doi:10.1016/S0140-6736(10)61259-7
[29] McAlister, F.A., Wiebe, N., Ezekowitz, J.A., Leung, A.A. and Armstrong, P.W. (2009) Meta-analysis: Beta-blocker dose, heart rate reduction, and death in patients with heart failure. Annals of Internal Medicine, 150, 784-794.
[30] Hori, M., Sasayama, S., Kitabatake, A., Toyooka, T., Handa, S., Yokoyama, M., Matsuzaki, M., Takeshita, A., Origasa, H., Matsui, K., et al. (2004) Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: The multicenter carvedilol heart failure dose assessment (MUCHA) trial. American Heart Journal, 147, 324330. doi:10.1016/j.ahj.2003.07.023
[31] Bouvy, M.L., Heerdink, E.R., Leufkens, H.G., Hoes, A.W. (2003) Patterns of pharmacotherapy in patients hospitalised for congestive heart failure. European Journal of Heart Failure, 5, 195-200. doi:10.1016/S1388-9842(02)00256-8

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.